Consistent time-varying association between ctDNA and post-resection colon and rectal cancer recurrence: The β-CORRECT study
Year: 2026
Type: article
Study design: Observational Study
Abstract: In this retrospective study of 468 patients with Stage II, III, or resectable Stage IV colorectal cancer (CRC), the association between circulating tumor DNA (ctDNA) detected with a tumor-informed molecular residual disease (MRD) assay and recurrence was evaluated. Tumor DNA and RNA sequencing of tumors were also performed to assess associations of tumor genomic alterations and expression with ctDNA status, DFS, and site of recurrence. Among 417 patients with a median follow-up of 1.9 years, ctDNA detection was strongly associated with shorter DFS during surveillance (HR 36.6), post-surgery (HR 7.5) and post-definitive therapy (HR 24.0), independent of clinicopathological factors. Each 10-fold increase in ctDNA level was associated with a two-fold increase in recurrence risk. Median lead time between ctDNA detection and clinical recurrence was 97 days. Among ctDNA-positive patients, adjuvant chemotherapy was associated with improved DFS (HR = 0.3), whereas no benefit was observed among ctDNA-negative patients (HR = 1.8). Significant interactions were observed between ctDNA status and RAS/BRAF alterations and WNT and MAPK pathway alterations. RNA sequencing identified distinct expression patterns associated with the epithelial-mesenchymal transition. These findings support ctDNA as an independent prognostic marker in resected CRC and identify molecular features associated with MRD and recurrence risk.
Source: Scientific Reports
Authors: Tadayoshi Hashimoto, Yoshiaki Nakamura, Gregory S. Young, Darl D. Flake II, Mohammad Abbasi, David W. Hall, Melanie R. Palomares, Somasundaram Subramaniam, Judith Frederick, Matthew Wallace, Eiji Oki, Daisuke Kotani, Saori Mishima, Jun Watanabe, Hiromichi Ebi, Masahito Kotaka, Kentaro Yamazaki, Hiroya Taniguchi, Yusuke Suwa, Keiji Hirata, Naoya Akazawa, Kozo Kataoka, Hideaki Bando, Ichiro Takemasa, Takeshi Kato, Gina Costa, Amin Mazloom, Jorge Garces, Frederick Baehner, Takayuki Yoshino, Exact Sciences MRD Group, Sarah Abdul-Wajid, Rizi Ai, Nila Balendra, Gargi Basu, Flavio Beas, Garrett Brady, Benjamin Camptell, Gloria Chan Johnson, Daniel Cuevas, Nikolas Delgado, Aimee Foreman, Gabriel Fung, Frankie Garcia-Patrick, Greg Grasse, John Hu, Scott Hunicke-Smith, Paige Innis, Andrea Johnson, Janine LoBello, Steve Lockton, Tara Marti, Suzanne Melanson, Hannah Mooney, Naoki Nariai, Zongtai Qi, Cole Richwine, Joseph Rose, Emad Samani, Satish Seerapu, Bingbing Song, Mayumi Smyers, Jessica Talamante, Nishitha Therala, Clem Uwimana, Michal Wojcik, Martin You, Jenny You
Institutions: National Cancer Centre Japan, National Cancer Center Hospital East, University of Oxford, Exact Sciences (United States), Kyushu University, Kansai Medical University, Aichi Cancer Center, Aichi Cancer Center Research Institute, Sano Hospital, Shizuoka Cancer Center, Aichi Cancer Center Hospital, Yokohama City University Medical Center, University of Occupational and Environmental Health Japan, Sendai Medical Center, Sendai City Medical Center, Sendai Open Hospital, Hyogo Medical University, Osaka Police Hospital, Osaka National Hospital
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,690
Awards: G158904782, G9001396335
OpenAlex ID: W7235525061
